

A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma [Corrigendum]

Liu Y, Sheng L, Hua H, Zhou J, Zhao Y, Wang B. *Cancer Manag Res.* 2023;15:651–666.

The authors have advised [Table 2](#) on pages 654-656, is incorrect. The correct [Table 2](#) is as follows.

Table 2 Baseline characteristics of patients

Characteristic	Training Set N (%)	Validation Set N (%)	p
Age(years)			0.423
≤60years	92(43.2)	34(38.2)	
>60years	121(56.8)	55(61.8)	
Gender			0.928
Male	105(49.3)	44(49.4)	
Female	108(50.7)	45(50.6)	
Ann Arbor stage			0.232
I/II	107(50.2)	38(42.7)	
III/IV	106(49.8)	51(57.3)	
LDH level(U/L)			0.550
≤245	144(67.6)	57(64.0)	
>245	69(32.4)	32(36.0)	
EN site involvement			0.121
<2EN sites	162(76.1)	60(67.4)	
≥2 EN sites	51(23.9)	29(32.6)	
ECOG PS			0.345
0–1	188(88.3)	75(84.3)	
≥2	25(11.7)	14(15.7)	
B symptoms			0.093
Yes	35(16.4)	22(24.7)	
No	178(83.6)	67(75.3)	
COO(Hans)			0.960
GCB	94(44.1)	39(43.8)	
Non-GCB	119(55.9)	50(56.2)	
Response			0.074
CR+PR	183(85.9)	69(77.5)	
SD+PD	30(14.1)	20(22.5)	
Combined operation			0.313
Yes	80(37.6)	28(31.5)	
No	133(62.4)	61(68.5)	
Combined radiotherapy			0.567
Yes	57(26.8)	21(23.6)	
No	156(73.2)	68(76.4)	

(Continued)

Table 2 (Continued).

Characteristic	Training Set N (%)	Validation Set N (%)	p
NLR <4.03 ≥4.03	149(70.0) 64(30.0)	60(67.4) 29(32.6)	0.663
PLR <201.75 ≥201.75	139(65.3) 74(34.7)	64(71.9) 25(28.1)	0.284
LMR <1.91 ≥1.91	57(26.8) 156(73.2)	39(43.8) 50(56.2)	0.004
AGR <1.48 ≥1.48	107(50.2) 106(49.8)	60(67.4) 29(32.6)	0.006
CAR <0.32 ≥0.32	156(73.2) 57(26.8)	59(66.3) 30(33.7)	0.224
SII <878.73 ≥878.73	149(70.0) 64(30.0)	59(66.3) 30(33.7)	0.531
SIRI <1.38 ≥1.38	118(55.4) 95(44.6)	43(48.3) 46(51.7)	0.261
PNI <43.55 ≥43.55	75(35.2) 138(64.8)	36(40.4) 53(59.6)	0.389
mGPS 0 1 2	151(70.9) 34(12.0) 28(13.1)	57(64.0) 14(15.7) 18(20.2)	0.287
β-2 MG <2.50 ≥2.50	152(71.4) 61(28.6)	60(67.4) 29(32.6)	0.494
MYC Negative Positive Unknown	75(35.2) 64(30.0) 74(34.7)	23(25.8) 26(29.2) 40(44.9)	0.179
BCL2 Negative Positive Unknown	75(35.2) 123(57.7) 15(7.0)	28(31.5) 45(50.6) 16(17.9)	<0.001
Ki67 <90% ≥90%	137(64.3) 76(35.7)	57(64.0) 32(36.0)	0.964

(Continued)

Table 2 (Continued).

Characteristic	Training Set N (%)	Validation Set N (%)	p
IPI			0.006
Low	102(47.9)	38(42.7)	
Low-intermediate	50(23.5)	18(20.2)	
High-intermediate	47(22.1)	15(16.9)	
High	14(6.6)	18(20.2)	
NCCN-IPI			0.029
Low	33(15.5)	13(14.6)	
Low-intermediate	112(52.6)	38(42.7)	
High-intermediate	59(27.7)	26(29.2)	
High	9(4.2)	12(13.5)	

Abbreviations: AGR, albumin to globulin ratio; COO, cell of origin; CAR, C-reactive protein to albumin ratio; CR, complete remission; EN, extranodal; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GCB, germinal center B-cell-like; IPI, International Prognostic Index; LDH, lactate dehydrogenase; LMR, lymphocyte to monocyte ratio; mGPS, modified Glasgow prognostic score; NCCN, National Comprehensive Cancer Network; NLR, neutrophil to lymphocyte ratio; PR, partial remission; PD, progressive disease; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index; SD, stable disease; SIRI, system inflammation response index; SII, systemic immune-inflammation index; β -2 MG, β -2 microglobulin.

Page 663, Figure 6 caption, the text “(D) OS of BCL2 \geq 50%; (E) OS of MYC \geq 40%” should read “(D) OS of MYC \geq 40%; (E) OS of BCL2 \geq 50%”.

The authors apologize for these errors and advise they do not affect the results of the paper.